Fine Structure Ventures

Investment decisions appear to be made by a small, flat team. Jennifer Uhrig, Shyam Kamadolli and David Needell are named across the largest number of disclosed portfolio positions, spanning Fund I and Fund II companies in fusion energy, steel decarbonization, satellite relays, space launch and edge AI hardware. The firm does not designate a managing partner or CEO in its public materials and emphasizes a collaborative, specialist decision-making structure.

The firm leans on deep academic and national-lab networks to access innovation before spinout. Several portfolio companies trace roots to the MIT Plasma Science and Fusion Center (Commonwealth Fusion Systems, Quaise Energy), the MIT spinout ecosystem (Osmoses), and Department of Energy national laboratories (Aalo Atomics, Palo Alto Veterans Institute). The investment team's collective PhDs in physics, chemistry and engineering likely provide direct scientist-to-scientist sourcing long before an institutional Series A.

Available evidence points to direct equity only. The firm lists only individual portfolio companies on its website, refers to board representation at over 80% of holdings, and discloses no fund-of-funds, SPV or co-investment-vehicle activity. There is no mention of GP stakes, LP interests in other venture firms, or a separate allocation to outside managers.

The firm self-identifies as covering the full lifecycle, from pre-seed to pre-IPO, but its disclosed activity tilts toward early-stage science bets. Fund I (vintage years 2020–2021) includes pre-product and early-commercialization companies such as Mainspring Energy, Osmoses and Nitricity. Fund II (2022–2025) extends the same deep-tech theme to slightly later-stage platform companies like Aalo Atomics and pH7 Technologies.

The firm’s five published categories — aerospace, biology, computing, energy, and materials — function as a negative screen for everything outside them. There are no disclosed portfolio companies in enterprise software, fintech, consumer internet, entertainment, or business services. The firm does not list healthcare services, diagnostics or therapeutics as categories, though biology holdings (Constructive Bio, Nulixir, Debut Biotech) touch industrial biotech and food tech rather than pharma.

No philanthropic foundation, donor-advised fund or charitable vehicle affiliated with Fine Structure Ventures has been disclosed. The firm’s website references no impact or concessionary capital allocation separate from its venture funds. All portfolio activity appears to be conducted through the venture management company.

The firm co-invests with breakthrough-energy backers and government-linked entities — Commonwealth Fusion Systems counts leading clean-energy investors, and Aalo Atomics secured approval to build at Idaho National Laboratory — but Fine Structure Ventures does not describe itself as a co-investment specialist. It has not disclosed a formal LP co-investment program or club-deal infrastructure common among multi-family-office platforms.